"The US Food and Drug Administration (FDA) has received a small number of reports of adverse events thought to be associated with CT imaging of some implantable and wearable electronic devices, such as insulin pumps, cardiac implantable electronic"...
Fludeoxyglucose F 18 Injection
Fludeoxyglucose Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Fludeoxyglucose F 18 Injection (fdg) is a positron emitting radiopharmaceutical used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). Fludeoxyglucose F 18 Injection is used to assist assessment of cancer, coronary artery disease, or epileptic seizures. Side effects from Fludeoxyglucose F 18 Injection are uncommon. Infrequent side effects of Fludeoxyglucose F 18 Injection include allergic reactions, itching, rash, and water retention.
The recommended dose of Fludeoxyglucose F 18 Injection (fdg) for an adult (70 kg) is 185-370 MBq (5-10 mCi), as an intravenous injection for studies of malignancy, cardiology and epilepsy. Use in patients with diabetes mellitus or hyperglycemia has not been well studied. It is recommended that patients be normoglycemic when undergoing PET imaging with Fludeoxyglucose F 18 Injection (fdg). Other drugs may interact with Fludeoxyglucose. Tell your doctor all medications you use. Talk to your doctor about taking Fludeoxyglucose if you are pregnant or breastfeeding.
Our Fludeoxyglucose F 18 Injection (fdg) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Fludeoxyglucose FDA Prescribing Information: Side Effects
The Fludeoxyglucose F 18 Injection (fdg) safety database for epilepsy included of 374 patients. Of these, 245 were male and 105 were female. For 24 patients, gender was not specified. The mean age was 47.8 years (range under 2 to over 65 years). Eighteen patients were between the age of 0 and 2 years; 42 patients were between the ages of 2 and 21 years; 213 patients were between 21 and 65 years; 98 patients were older than 65 years; and the ages of 3 male patients were not specified. A racial distribution is not available. In this database, adverse drug reactions that required medical intervention were not reported. In a small, 42 patient subset of the 374 patients studied, 4 patients had transient hypotension, 6 had hypo- or hyperglycemia and 3 had transient increases in alkaline phosphatase.
Reviews of the oncology and cardiology literature did not reveal reported adverse reactions.
Read the entire FDA prescribing information for Fludeoxyglucose (FDG)
Additional Fludeoxyglucose F 18 Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.